Patents by Inventor Timothy Davenport
Timothy Davenport has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230216076Abstract: A fuel cell assembly including a fuel cell stack having a first stack end and a second stack end, a first end plate located at the first stack end, and a second end plate located at the second stack end. The fuel cell stack being interposed between the first end plate and the second end plate. The fuel cell assembly including a compliant assembly extending from a first end to a second end located opposite the first end. The compliant assembly is configured to anchor together the fuel cell stack, the first end plate, and the second end plate. The compliant assembly include a rod extending from a first rod end to a second rod end. The compliant assembly also includes a connector body secured to the rod at or proximate the first rod end and an anchoring mechanism secured to the connector body.Type: ApplicationFiled: January 6, 2022Publication date: July 6, 2023Inventors: Andrzej Ernest Kuczek, Robert Mason Darling, Kristoffer Ridgeway, Timothy Davenport
-
Patent number: 11664518Abstract: A redox flow battery includes a redox flow cell and a supply and storage system external of the redox flow cell. The supply and storage system includes first and second electrolytes for circulation through the redox flow cell. The first electrolyte is a liquid electrolyte having electrochemically active manganese species with multiple, reversible oxidation states in the redox flow cell. The electrochemically active manganese species may undergo reactions that cause precipitation of manganese oxide solids. The first electrolyte includes an inhibitor that limits the self-discharge reactions. The inhibitor includes an oxoanion compound.Type: GrantFiled: May 21, 2021Date of Patent: May 30, 2023Assignee: RAYTHEON TECHNOLOGIES CORPORATIONInventors: Timothy Davenport, James D. Saraidaridis, Robert Mason Darling
-
Publication number: 20220376286Abstract: A redox flow battery includes a redox flow cell and a supply and storage system external of the redox flow cell. The supply and storage system includes first and second electrolytes for circulation through the redox flow cell. The first electrolyte is a liquid electrolyte having electrochemically active manganese species with multiple, reversible oxidation states in the redox flow cell. The electrochemically active manganese species may undergo reactions that cause precipitation of manganese oxide solids. The first electrolyte includes an inhibitor that limits the self-discharge reactions. The inhibitor includes an oxoanion compound.Type: ApplicationFiled: May 21, 2021Publication date: November 24, 2022Inventors: Timothy Davenport, James D. Saraidaridis, Robert Mason Darling
-
Publication number: 20080076759Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: September 28, 2007Publication date: March 27, 2008Applicant: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Patent number: 7285662Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: April 18, 2005Date of Patent: October 23, 2007Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Publication number: 20060178372Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: April 4, 2006Publication date: August 10, 2006Applicant: AstraZeneca ABInventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Patent number: 7045514Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: July 12, 2004Date of Patent: May 16, 2006Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Patent number: 7026314Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: GrantFiled: January 15, 2002Date of Patent: April 11, 2006Assignee: AstraZeneca ABInventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20060019947Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B in antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: ApplicationFiled: September 16, 2005Publication date: January 26, 2006Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20050182050Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: April 18, 2005Publication date: August 18, 2005Applicant: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Publication number: 20050096312Abstract: Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: November 1, 2002Publication date: May 5, 2005Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Publication number: 20050085457Abstract: Provided herein is a compound having the formula (I) (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: November 1, 2002Publication date: April 21, 2005Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Publication number: 20050009818Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: July 12, 2004Publication date: January 13, 2005Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Patent number: 6812225Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: January 16, 2002Date of Patent: November 2, 2004Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Publication number: 20040110745Abstract: Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.Type: ApplicationFiled: July 16, 2003Publication date: June 10, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20040087575Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: ApplicationFiled: July 16, 2003Publication date: May 6, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20040082591Abstract: Provided herein is a compound having the formula (I) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: July 16, 2003Publication date: April 29, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20030013708Abstract: Provided herein is a compound having the formula (I): 1Type: ApplicationFiled: January 16, 2002Publication date: January 16, 2003Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley